GERN - Geron Corporation
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the appointment of Constantine Chinoporos as Executive Chairman of the company's board of directors, effective immediately.
FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 1,700,000 shares of Geron common stock to Chinmaya Rath, Geron's new Chief Business Officer, as an inducement material to his acceptance of employment with Geron.
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies
Geron Corporation delivered Q1'26 Rytelo revenues of $51.8M, up 8% sequentially, with two consecutive quarters of demand growth. GERN maintained 2026 guidance, with net product revenues of $220M-$240M expected. Management is now prioritizing high-volume community accounts, aiming to shift sales mix from academic centers to the broader 80% community-driven market.
FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m.
Geron has secured FDA approval for RYTELO in low- to intermediate-1 risk MDS, marking a pivotal milestone after decades of development. Despite disappointing initial RYTELO sales, GERN forecasts 2026 revenues of $220–$240 million and is executing targeted commercial and European expansion strategies. A new management team is in place, with significant liquidity ($341 million) and a cash runway of ~2.7 years supporting ongoing pipeline and commercial efforts.
Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population Additional presentations at EHA 2026 and ASCO 2026 include abstracts related to ongoing myelofibrosis and AML clinical programs FOSTER CITY, Calif.
Geron Corporation (GERN) Q1 2026 Earnings Call Transcript
Geron (GERN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago.
Achieved $51.8 million in RYTELO ® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Strengthened leadership team with appointments of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary and Patricia S. Andrews and Constantine Chinoporos to Board of Directors Ended Q1 2026 with cash, cash equivalents, restricted cash and marketable securities of $341 million Company to host conference call and webcast today, May 6, 2026, at 8:00 a.m.
FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences: Bank of America Securities 2026 Healthcare Conference Presentation on Tuesday, May 12 at 4:35 p.m.
FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its first quarter 2026 financial results and business highlights before the market opens on Wednesday, May 6, 2026 via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase an aggregate of 855,000 shares of common stock to nine newly hired employees as an inducement material to such employees' acceptance of employment with Geron.